Filtered Products

Prostate cancer (PCa) ranks as the most prevalent malignancy in men worldwide and represents the second leading cause of cancer-related death among the male population. Epidemiological statistics from the United States predict that approximately 20 million new cancer cases and 10 million cancer-related deaths occur globally every year. The number of new global cancer cases is projected to rise to 30 million by 2040, indicating that cancer incidence will keep increasing in the future. Widespread tumor heterogeneity exists among patients, which creates an urgent clinical demand for developing more effective therapeutic strategies. As an emerging in vitro/ex vivo model system, organoids serve as highly promising research vehicles for basic and translational studies of prostate cancer. Organoids are capable of recapitulating the core genomic, histopathological and phenotypic features of parental tumors. With the support of genetic manipulation technology, researchers can accurately elucidate the molecular regulatory mechanisms underlying tumor initiation and drug resistance. This model system features relatively manageable costs; it can simulate tumor heterogeneity in vitro and reconstruct the interactions between tumor cells and the tumor microenvironment.